GeneThera Inc
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. It offers treatments for zoonotic diseases, such as COVID -19 disease; paratuberculosis (Johne's disease) that is in Stage III clinical phase; mad cow and chronic wasting diseases; and E.coli and salmonella infections, as well as develops vaccine for mycobacte… Read more
GeneThera Inc (GTHR) - Total Liabilities
Latest total liabilities as of December 2022: $8.18 Million USD
Based on the latest financial reports, GeneThera Inc (GTHR) has total liabilities worth $8.18 Million USD as of December 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
GeneThera Inc - Total Liabilities Trend (1997–2022)
This chart illustrates how GeneThera Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
GeneThera Inc Competitors by Total Liabilities
The table below lists competitors of GeneThera Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Clone Algo Technologies Inc
PINK:CATI
|
USA | $455.42K |
|
Millerful No. 1 REIT
TW:01010T
|
Taiwan | NT$5.31 Billion |
|
Sweden BuyersClub AB
ST:BUY
|
Sweden | Skr15.52 Million |
|
Faysal Bank Ltd
KAR:FABL
|
Pakistan | PKRs1.33 Trillion |
|
Ondo InsurTech PLC
LSE:ONDO
|
UK | GBX11.02 Million |
|
Auxilia SA
WAR:AUX
|
Poland | zł33.88 Million |
|
ANGES MG
MU:AJW
|
Germany | €2.20 Billion |
|
China Changjiang Mining & New Energy Co Ltd
PINK:CHJI
|
USA | $3.67 Million |
Liability Composition Analysis (1997–2022)
This chart breaks down GeneThera Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1297.84 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GeneThera Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GeneThera Inc (1997–2022)
The table below shows the annual total liabilities of GeneThera Inc from 1997 to 2022.
| Year | Total Liabilities | Change |
|---|---|---|
| 2022-12-31 | $8.18 Million | 0.00% |
| 2021-12-31 | $8.18 Million | +6.33% |
| 2020-12-31 | $7.69 Million | +10.80% |
| 2019-12-31 | $6.94 Million | -6.10% |
| 2018-12-31 | $7.39 Million | 0.00% |
| 2017-12-31 | $7.39 Million | +3.82% |
| 2016-12-31 | $7.12 Million | +6.77% |
| 2015-12-31 | $6.67 Million | +15.92% |
| 2014-12-31 | $5.75 Million | +8.19% |
| 2013-12-31 | $5.32 Million | +14.99% |
| 2012-12-31 | $4.63 Million | +50.77% |
| 2011-12-31 | $3.07 Million | +21.95% |
| 2008-12-31 | $2.52 Million | +47.81% |
| 2007-12-31 | $1.70 Million | +19.98% |
| 2006-12-31 | $1.42 Million | +65.36% |
| 2005-12-31 | $857.78K | -21.77% |
| 2004-12-31 | $1.10 Million | -15.67% |
| 2003-12-31 | $1.30 Million | +22.10% |
| 2002-12-31 | $1.06 Million | +401.18% |
| 2001-12-31 | $212.49K | +713.99% |
| 2000-12-31 | $26.11K | -89.42% |
| 1999-12-31 | $246.80K | -46.60% |
| 1998-12-31 | $462.13K | +2.70% |
| 1997-12-31 | $450.00K | -- |